Company Recently Introduced BC-SeraPro Diagnostic in Twelve Middle Eastern Countries
Power3 Medical Products, Inc. (OTCBB: PWRM, www.power3medical.com), a leading proteomics company specializing in the development and commercialization of diagnostic tests for the early detection of breast cancer and neurodegenerative diseases, applauds Laura Bush’s campaign in the Middle East for breast cancer awareness. The First Lady’s campaign takes place concurrently with Power3’s launch of BC-SeraPro, a diagnostic blood test for breast cancer, in twelve Middle Eastern countries.
“The incidence of breast cancer in the Middle East are some of the highest around the world,” begins Steven B. Rash, Chief Executive Officer of Power3 Medical. “Laura Bush’s campaign emphasizes the need for additional methods of early detection as more and more women are diagnosed with the disease after it has already progressed to later stages. We believe BC-SeraPro provides a solution to detect breast cancer at an earlier stage, thereby alleviating the problems that so many Middle Eastern women face because of late-stage detection. We are currently in discussions with several international and domestic partners as we implement our strategic plan to expand our geographical distribution of the test.”
BC-SeraPro is the first proteomics-based blood serum diagnostic test to be used for the early screening and diagnosis of breast cancer. In October, the company announced its signed agreement with Financial Advisory House’s Medical Equipment Suppliers division (FAH), which allows for the marketing and distribution of BC-SeraPro in: Bahrain, Egypt, Iraq, Jordan, Kuwait, Lebanon, Saudi Arabia, Oman, Qatar, Syria, United Arab Emirates, and Yemen.
About Power3 Medical Products
Power3 Medical Products, Inc. (OTCBB: PWRM, www.Power3Medical.com), is a leading proteomics company engaged in the commercialization of protein biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets for cancer and neurodegenerative diseases. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets. Diagnostic tests are targeted toward markets with critical unmet needs in areas such as breast cancer and neurodegenerative disease. Power3 has signed its first distribution agreement to provide its blood serum diagnostic for breast cancer, BC-SeraPro, in twelve Middle Eastern countries before the end of 2007. Power3 operates a state-of-the-art CLIA certified proteomics laboratory in The Woodlands (Houston), Texas, and recently announced an agreement forming a joint venture (CRO) with NeoGenomics, Inc. (NASDAQ: NGNM - News) of Fort Myers, Florida, to commercialize Power3’s portfolio of IP, centering on the 543 biomarkers the Company has discovered from a broad range of diseases as the basis of blood-based tests for breast cancer, ALS, Alzheimer’s, and Parkinson’s Diseases.
Forward Looking Statement
This press release contains forward-looking statements within the meaning of section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. With the exception of historical information contained herein, the matters discussed in this press release involve risk and uncertainties. Actual results could differ materially from those expressed in any forward-looking statement.
Power3 Medical Products, Inc.
Steven B. Rash, 281-466-1600
srash@power3medical.com
or
The Investor Relations Group
Investor Relations:
Adam Holdsworth / Rachel Colgate /
Erica Ruderman, 212-825-3210
or
Media Relations:
Susan Morgenbesser / Janet Vasquez, 212-825-3210